Immuneering Corporation
NASDAQ:IMRXBiotechnology
Healthcare
$3.50 -0.14%
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
52W Low $2.29High $10.08
Volume 0.73M
Average 1.38M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$45.34M
FY 2025 · Annual
Investing Cash Flow
-$88.74M
FY 2025 · Annual
Financing Cash Flow
$226.58M
FY 2025 · Annual
+4172.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.54M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Depreciation & Amortization | 159.07K | 796.79K | 352.08K | 385.07K | 698.89K |
| Deferred Income Tax | (307.49K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.8M | 0 | 5.73M | 6.5M | 0 |
| Change in Working Capital | 900.42K | 1.72M | (974.64K) | (925.38K) | 3.82M |
| Accounts Receivables | 279.71K | 233.62K | 12.42K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (130.4K) | 1.76M | (1.11M) | (112.14K) | (400.8K) |
| Other Working Capital | 751.1K | (276.56K) | 119.84K | (813.24K) | 4.22M |
| Other Non-Cash Items | 130.24K | 3.9M | (601.59K) | 75.98K | 6.16M |
| Operating Cash Flow | (30.85M) | (44.1M) | (48.97M) | (55M) | (45.34M) |
| Capital Expenditures | (60.79K) | (742.49K) | (342.75K) | (84.88K) | (142.23K) |
| Acquisitions (Net) | 70.35K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (75.63M) | (50.1M) | (44.66M) | (5.41M) | (88.6M) |
| Sales of Investments | 75.62M | 92.68M | 52.3M | 31.93M | 0 |
| Other Investing Activities | (75.62M) | 0 | 0 | 0 | 247 |
| Investing Cash Flow | (75.62M) | 41.83M | 7.3M | 26.43M | (88.74M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 120.32M | 19K | 28.2M | 4.24M | 226.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (842.76K) | 0 | 241.07K | 1.07M | (147) |
| Financing Cash Flow | 144.26M | 19K | 28.44M | 5.3M | 226.58M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.8M | (2.25M) | (13.23M) | (23.26M) | 92.5M |
| Free Cash Flow | (30.91M) | (44.84M) | (49.31M) | (55.08M) | (45.49M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$56.0M
+ D&A$698.9K
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$3.8M
+ Other Non-Cash$6.2M
= Operating Cash Flow-$45.3M
- Capex-$142.2K
= Free Cash Flow-$45.5M
Analysis
FY2025 free cash flow is -$45.5M. FCF conversion is 81.2% of net income. Operating cash flow was -$45.3M, with capex of -$142.2K. The largest bridge item is Other Non-Cash at $6.2M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 3 | Initial statement of beneficial ownership | Nov 9, 2026 | |
| 10-Q | Quarterly report | Oct 29, 2026 | |
| 8-K | Current report | Oct 29, 2026 |
Does IMRX generate free cash flow?
Immuneering Corporation (IMRX) generated -$45.49M of free cash flow in fiscal 2025.
How much operating cash flow does IMRX produce?
Operating cash flow was -$45.34M, before capital expenditures of $142,225.00.
Continue the stock analysis
Jump to another research area for this company.